Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (131-140 of 376) with videos related to

Pageof 38
Sort By:
Biochimica Et Biophysica Acta|September 11, 2012
The cholesterol content of the erythrocyte membrane is an important determinant of phosphatidylserine exposureRob van Zwieten, Andrea E Bochem, Petra M Hilarius, et al.
JAMA Cardiology|August 3, 2022
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization StudyArjen J Cupido, Laurens F Reeskamp, Aroon D Hingorani, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Journal of Clinical Lipidology|December 7, 2016
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported diseaseBarbara Sjouke, Joep C Defesche, Merel L Hartgers, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Atherosclerosis|December 22, 2016
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population studyNicolas Perrot, Rutger Verbeek, Manjinder Sandhu, et al.
Journal of Clinical Lipidology|February 24, 2019
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) studyIlse K Luirink, Marjet J A M Braamskamp, Albert Wiegman, et al.
Intensive Care Medicine Experimental|November 26, 2024
Target-controlled dialysis for antibiotics (TCD-ABx)Alexander Dejaco, Christoph Dorn, Constantin Lier, et al.
Journal of Clinical Lipidology|January 5, 2023
Counseling couples at risk of having a child with homozygous familial hypercholesterolemia - Clinical experience and recommendationsTycho R Tromp, M Doortje Reijman, Albert Wiegman, et al.
Pageof 38

Showing results (131-140 of 376) with videos related to

Sort By:
Pageof 38
Biochimica Et Biophysica Acta|September 11, 2012
The cholesterol content of the erythrocyte membrane is an important determinant of phosphatidylserine exposureRob van Zwieten, Andrea E Bochem, Petra M Hilarius, et al.
JAMA Cardiology|August 3, 2022
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization StudyArjen J Cupido, Laurens F Reeskamp, Aroon D Hingorani, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Journal of Clinical Lipidology|December 7, 2016
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported diseaseBarbara Sjouke, Joep C Defesche, Merel L Hartgers, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Atherosclerosis|December 22, 2016
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population studyNicolas Perrot, Rutger Verbeek, Manjinder Sandhu, et al.
Journal of Clinical Lipidology|February 24, 2019
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) studyIlse K Luirink, Marjet J A M Braamskamp, Albert Wiegman, et al.
Intensive Care Medicine Experimental|November 26, 2024
Target-controlled dialysis for antibiotics (TCD-ABx)Alexander Dejaco, Christoph Dorn, Constantin Lier, et al.
Journal of Clinical Lipidology|January 5, 2023
Counseling couples at risk of having a child with homozygous familial hypercholesterolemia - Clinical experience and recommendationsTycho R Tromp, M Doortje Reijman, Albert Wiegman, et al.
Pageof 38